Answers are grounded in this paper and cite their sources.
Discussion highlights potential of allogeneic CAR T cells to improve glioblastoma therapy by addressing major limitations.
CRISPR/Cas9, might allow overcoming the two main limitations of allogeneic CAR T cells product, i.e., graft-vs.-host disease and host allorejection. Here, we will discuss how allogeneic CAR T cells could allow for multivalent approaches and alteration of the tumor microenvironment, potentially allowing the development of next generation therapies for the treatment of patients with GBM.
No takes yet. Share an insight, caveat, or question.
Bedoya et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: